Trademark
Full logoAbout Eli Lilly And Co
Eli Lilly is a pharmaceutical company that has become one of the most valuable in the world on the back of its GLP-1 franchise — Mounjaro for type 2 diabetes and Zepbound for obesity, both based on the molecule tirzepatide. The company's portfolio also includes leading drugs in oncology (Verzenio), immunology (Taltz, Olumiant), and Alzheimer's disease (Kisunla, approved in 2024). Founded in 1876 by Colonel Eli Lilly, a Civil War veteran and pharmacist, the company is headquartered in Indianapolis, Indiana. Lilly was the first company to commercially manufacture insulin in 1923 and remains one of the largest insulin producers in the world.
About the Eli Lilly And Co logo
The Eli Lilly And Co (LLY) logo is part of the Tickericons pack — a hand-crafted set of logos for every company in the S&P 500. Each logo is manually redrawn to a consistent grid, weight, and corner radius so LLY sits cleanly next to other tickers in cap tables, dashboards, equity research, and fintech UI.
You get two styles: the trademark (just the symbol, ideal for grids and tight UI) and the full logo (mark plus wordmark, ideal when there's room to breathe). Both ship as scalable SVG, high-resolution PNG, and reusable Figma components.
Is Eli Lilly And Co in the S&P 500?
Yes. Eli Lilly And Co (LLY) is a member of the S&P 500 and has been since Dec 31, 1970. It is classified under the Health Care sector and is also one of the mega-caps in the S&P 100. See every S&P 500 addition and removal.
Other Health Care companies
See all →
abtAbbott LaboratoriesMar 4, 195725,460
abbvAbbVieDec 31, 20125,069
aAgilent TechnologiesJun 5, 20009,661
algnAlign TechnologyJun 19, 20173,438
amgnAmgenJan 2, 199212,738
baxBaxter InternationalSep 30, 197219,771
bdxBecton Dickinson and CoSep 30, 197219,771
techBio-Techne CorporationAug 30, 20211,905
biibBiogenNov 13, 20038,405
bsxBoston Scientific CorporationFeb 24, 199511,589
Get all S&P 500 logos
One-time payment. SVG, PNG, and a Figma library. Free updates as the index changes.


